PLX

Protalix BioTherapeutics, Inc. [PLX] Stock Forecast

Q: What is Protalix BioTherapeutics, Inc. stock symbol ?

Protalix BioTherapeutics, Inc. is a US stock, located in Hackensack of Nj and trading under the symbol PLX

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?

PLX Stock Summary

Earnings have grown 37.48% per last year.

EPS has been increasing for the past 3 years (Yearly statements)

EPS has increased from the previous year and become positive (Yearly statements)

Earnings are expected to fall -100% next year

EPS has been decreasing for the past 3 quarters (Quarter statements)

PLX has less than 1 year of cash runway

Top 10 Correlated ETFs

PLX

Top 10 Correlated Stocks

PLX

In the News

PLX Financial details

Company Rating

Neutral

Market Cap

86.2M

Income

8.31M

Revenue

65.49M

Book val./share

0.46

Cash/share

0.61

Dividend

Dividend %

Employees

208

Optionable

Shortable

Yes

Earnings

02 May 2024

P/E

11.85

Forward P/E

PEG

-0.84

P/S

P/B

3.29

P/C

1.8

P/FCF

-14.7

Quick Ratio

1.15

Current Ratio

1.67

Debt / Equity

0.78

LT Debt / Equity

0.14

EPS (TTM)

0.13

EPS next Y

EPS next Q

EPS this Y

-138.71%

EPS next Y

EPS next 5Y

EPS last 5Y

NAN%

Revenue last 5Y

3.67%

Revenue Q/Q

1.36%

EPS Q/Q

223.44%

SMA20

SMA50

SMA100

Inst Own

10.83%

Inst Trans

0.7%

ROA

12%

ROE

63%

ROC

0.31%

Gross Margin

74%

Oper. Margin

21%

Profit Margin

17%

Payout

Shs Outstand

Shs Float

Target Price

52W Range

1.17-3.55

52W High

-63.4%

52W Low

+9.8%

RSI

Rel Volume

0.78

Avg Volume

341.3K

Volume

265.66K

Perf Week

-12.86%

Perf Month

-24.79%

Perf Quarter

-26.31%

Perf Half Y

-26.8%

Beta

0.889

Volatility

0.04%, 0.1%

Prev Close

-4.52%

Price

1.098

Change

-4.52%

PLX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2023-12-31

Metric	2019-12-31	2020-12-31	2021-12-31	2022-12-31	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	3.69	2.16	0.87	0.98	0.97
Net income per share	-1.77	-0.51	-0.77	-0.31	0.12
Operating cash flow per share	-1.3	-0.9	-0.23	-0.52	-0.02
Free cash flow per share	-1.35	-0.92	-0.27	-0.53	-0.04
Cash per share	1.2	1.32	1.77	0.46	0.66
Book value per share	-4.74	-0.93	-0.14	-0.22	0.5
Tangible book value per share	-4.74	-0.93	-0.14	-0.22	0.5
Share holders equity per share	-4.74	-0.93	-0.14	-0.22	0.5
Interest debt per share	4.64	2.54	0.93	0.74	0.44
Market cap	48.67M	105.81M	36.71M	66.41M	120.17M
Enterprise value	91.8M	151.94M	31.2M	82.77M	122.82M
P/E ratio	-1.85	-7.1	-1.08	-4.45	14.46
Price to sales ratio	0.89	1.68	0.96	1.39	1.83
POCF ratio	-2.51	-4.05	-3.57	-2.66	-91.18
PFCF ratio	-2.44	-3.95	-3.13	-2.59	-48.71
P/B Ratio	-0.69	-3.91	-6.08	-6.24	3.58
PTB ratio	-0.69	-3.91	-6.08	-6.24	3.58
EV to sales	1.68	2.42	0.81	1.74	1.88
Enterprise value over EBITDA	-10.56	48.27	-1.56	-7.68	10.54
EV to operating cash flow	-4.74	-5.82	-3.03	-3.31	-93.19
EV to free cash flow	-4.59	-5.68	-2.66	-3.23	-49.78
Earnings yield	-0.54	-0.14	-0.93	-0.22	0.07
Free cash flow yield	-0.41	-0.25	-0.32	-0.39	-0.02
Debt to equity	-0.87	-2.38	-5.55	-3.15	0.78
Debt to assets	1.34	0.95	0.45	0.6	0.31
Net debt to EBITDA	-4.96	14.66	0.27	-1.52	0.23
Current ratio	0.81	0.64	1.86	1.38	1.54
Interest coverage	-1.35	0.19	-2.72	-5.15	3.29
Income quality	1.06	4	0.37	1.67	-0.16
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	-0.11	-0.08	-0.1	-0.29	-0.39
Research and developement to revenue	0.82	0.61	0.78	0.62	0.26
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.03	0.03	0.14	0.03	0.87
Capex to revenue	-0.01	-0.01	-0.04	-0.01	-0.02
Capex to depreciation	-0.39	-0.5	-1.31	-0.58	-0.96
Stock based compensation to revenue	0.02	0.05	0.06	0.04	0.05
Graham number	13.73	3.27	1.54	1.23	1.17
ROIC	4.13	0.1	-0.76	-0.48	0.16
Return on tangible assets	-0.58	-0.22	-0.46	-0.27	0.1
Graham Net	-6.09	-1.66	0.22	-0.67	0.11
Working capital	-7.7M	-30.75M	28.49M	12.45M	24.4M
Tangible asset value	-70.32M	-27.04M	-6.04M	-10.64M	33.57M
Net current asset value	-83.24M	-39.25M	-18.04M	-21.55M	19.07M
Invested capital	-0.87	-2.38	-5.55	-3.15	0.78
Average receivables	4.71M	3.35M	2.72M	4.01M	4.93M
Average payables	5.85M	6.86M	7.1M	6.42M	5.09M
Average inventory	8.36M	10.62M	15.52M	17.38M	17.92M
Days sales outstanding	31.37	11.61	32.76	35.14	29.38
Days payables outstanding	217.59	242.4	155.97	109.21	68.61
Days of inventory on hand	273.21	439.15	400.83	313.06	302.47
Receivables turnover	11.64	31.45	11.14	10.39	12.42
Payables turnover	1.68	1.51	2.34	3.34	5.32
Inventory turnover	1.34	0.83	0.91	1.17	1.21
ROE	0.37	0.55	5.63	1.4	0.25
Capex per share	-0.04	-0.02	-0.03	-0.01	-0.02

Quarterly Fundamentals Overview

Last date of statement is 2023-12-31 for Q4

Metric	2022-12-31	2023-03-31	2023-06-30	2023-09-30	2023-12-31
	2.02K	2.02K	2.02K	2.02K	2.02K
Revenue per share	0.17	0.17	0.52	0.14	0.14
Net income per share	-0.07	-0.05	0.29	-0.03	-0.08
Operating cash flow per share	-0.05	-0.05	0.07	-0.1	0.05
Free cash flow per share	-0.06	-0.06	0.07	-0.1	0.05
Cash per share	0.43	0.57	0.72	0.57	0.61
Book value per share	-0.21	0.02	0.58	0.53	0.46
Tangible book value per share	-0.21	0.02	0.58	0.53	0.46
Share holders equity per share	-0.21	0.02	0.58	0.53	0.46
Interest debt per share	0.66	0.6	0.41	0.37	0.37
Market cap	70.34M	120.71M	134.32M	119.99M	129.85M
Enterprise value	86.7M	121.24M	112.1M	125.59M	132.5M
P/E ratio	-4.7	-9.64	1.74	-16.2	-5.37
Price to sales ratio	8.16	12.59	3.83	11.6	12.38
POCF ratio	-26.94	-40.26	27.01	-17.42	36.12
PFCF ratio	-24.91	-37.19	28.16	-16.36	38.82
P/B Ratio	-6.61	119.75	3.44	3.14	3.87
PTB ratio	-6.61	119.75	3.44	3.14	3.87
EV to sales	10.06	12.64	3.2	12.14	12.64
Enterprise value over EBITDA	-37.94	-53.01	5.35	-66.55	-24.99
EV to operating cash flow	-33.21	-40.44	22.54	-18.23	36.86
EV to free cash flow	-30.7	-37.35	23.51	-17.12	39.61
Earnings yield	-0.05	-0.03	0.14	-0.02	-0.05
Free cash flow yield	-0.04	-0.03	0.04	-0.06	0.03
Debt to equity	-3.15	33.3	0.67	0.68	0.78
Debt to assets	0.6	0.5	0.29	0.3	0.31
Net debt to EBITDA	-7.16	-0.23	-1.06	-2.97	-0.5
Current ratio	1.38	1.76	3.18	1.67	1.54
Interest coverage	-3.84	-3.79	15.65	-4.1	-7.25
Income quality	0.7	0.96	0.26	3.72	-0.59
Dividend Yield	0	0	0	0	0
Payout ratio	0	0	0	0	0
Sales general and administrative to revenue	-2.58	-0.2	-0.31	-0.63	0
Research and developement to revenue	0.65	0.61	0.13	0.35	0.3
Intangibles to total assets	0	0	0	0	0
Capex to operating cash flow	0.08	0.08	-0.04	0.06	-0.07
Capex to revenue	-0.02	-0.03	-0.01	-0.04	-0.02
Capex to depreciation	-0.77	-0.89	-0.7	-1.47	-0.8
Stock based compensation to revenue	0.06	0.06	0.01	0.11	0.13
Graham number	0.58	0.15	1.94	0.55	0.93
ROIC	-0.1	-0.07	0.28	-0.03	-0.08
Return on tangible assets	-0.07	-0.05	0.22	-0.02	-0.07
Graham Net	-0.63	-0.37	0.17	0.13	0.1
Working capital	12.45M	23.89M	50.47M	29.26M	24.4M
Tangible asset value	-10.64M	1.01M	39M	38.25M	33.57M
Net current asset value	-21.55M	-10.15M	24.16M	23.3M	19.07M
Invested capital	-3.15	33.3	0.67	0.68	0.78
Average receivables	6.62M	2.95M	2.68M	6.49M	7.1M
Average payables	5.75M	5.48M	4.2M	3.21M	3.72M
Average inventory	15.68M	18.55M	19.97M	20.61M	20.31M
Days sales outstanding	47.9	12.24	10.39	77.73	45.25
Days payables outstanding	220.1	148.93	48.37	57.28	43.9
Days of inventory on hand	630.94	592.31	287.43	396.99	193.55
Receivables turnover	1.88	7.35	8.66	1.16	1.99
Payables turnover	0.41	0.6	1.86	1.57	2.05
Inventory turnover	0.14	0.15	0.31	0.23	0.47
ROE	0.35	-3.11	0.5	-0.05	-0.18
Capex per share	0	0	0	-0.01	0

PLX Frequently Asked Questions

What is Protalix BioTherapeutics, Inc. stock symbol ?

Protalix BioTherapeutics, Inc. is a US stock , located in Hackensack of Nj and trading under the symbol PLX

What is Protalix BioTherapeutics, Inc. stock quote today ?

Protalix BioTherapeutics, Inc. stock price is $1.098 today.

Is Protalix BioTherapeutics, Inc. stock public?

Yes, Protalix BioTherapeutics, Inc. is a publicly traded company.

Something similar

Top by Market Cap

Top Correlated ETFs

Top Correlated Stocks

Similar Market Cap

Company Profile

Volume Average 341.3K
Market Capitalization 86.2M
Employee 208
CEO Mr. Dror Bashan
Headquarters Hackensack,NJ,US
IPO Date 1998-05-15
Website https://www.protalix.com

Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally. The company offers Elelyso for the treatment of Gaucher disease. Its product pipeline comprises PRX-102, a therapeutic protein candidate, which is in the last stage of clinical trials for the treatment of Fabry diseases; PRX-110, a proprietary plant cell recombinant form of human deoxyribonuclease I that has completed phase IIa clinical trials for the treatment of cystic fibrosis; PRX-115, a plant cell-expressed recombinant PEGylated Uricase for the treatment of gout; and PRX-119, a plant cell-expressed PEGylated recombinant human DNase I product candidate for the treatment of NETs-related diseases. The company has agreements and partnerships with Pfizer; Fundação Oswaldo Cruz (Fiocruz); and Chiesi Farmaceutici S.p.A. The company was founded in 1993 and is based in Hackensack, New Jersey.